Physician profile
Andrew D Dukowicz
NPI 1619063450
$4,150.48
in general payments reported to CMS, 2019-2025
32 companies · $1,644 in 2025
The $1,644 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.83 · 2020: $122 · 2021: $37.37 · 2022: $223 · 2023: $719 · 2024: $1,392 · 2025: $1,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,649 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,648.87 |
| Education | $105.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $767.39 | 2020-2025 | Stelara, Tremfya |
| Abbvie INC. | $739.65 | 2022-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $370.46 | 2023-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $234.18 | 2023-2025 | Ibsrela |
| Steris Corporation | $205.93 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $188.71 | 2024-2025 | Dupixent |
| Enterra Medical, INC. | $145.14 | 2025 | |
| Phathom Pharmaceuticals, INC. | $133.86 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $127.99 | 2025 | Sucraid |
| Medtronic, INC. | $126.06 | 2022 | |
| Pfizer INC. | $123.51 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $115.07 | 2021-2023 | Linzess |
| Madrigal Pharmaceuticals | $109.96 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.98 | 2023-2024 | Trulance, Xifaxan, Relistor |
| Covidien LP | $107.80 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $77.54 | 2023-2024 | Visiglide, Endocuff Vision, Endoclot Phs |
| Intercept Pharmaceuticals, INC. | $63.62 | 2025 | |
| Boston Scientific Corporation | $58.58 | 2022-2025 | Cre Pro, Captivator II |
| Laborie Medical Technologies Corp. | $52.40 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $45.18 | 2025 | Iqirvo |
| Pentax of America, INC. | $28.95 | 2024 | Pentax Medical, Inspira, C2 Cryoballoon Focal Controller |
| Alnylam Pharmaceuticals INC. | $26.16 | 2025 | Givlaari |
| Merck Sharp & Dohme LLC | $25.14 | 2023 | Dificid |
| Novo Nordisk INC | $23.79 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $22.52 | 2025 | Suflave |
| Vivus LLC | $21.98 | 2025 | Pancreaze |
| Lilly USA, LLC | $20.59 | 2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $18.95 | 2023 | |
| Organon LLC | $17.86 | 2025 | Hadlima |
| Celgene Corporation | $15.73 | 2023 | |
| Aimmune Therapeutics, INC. | $13.49 | 2025 | Zenpep |
| Genzyme Corporation | $13.31 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Dukowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.